Tag: Definium Therapeutics

Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug ...

The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...

Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the ...

Definium Therapeutics has reported positive Phase III results for its LSD-based medicine DT120 in generalised anxiety disorder, giving the company ...

Institutional investors are returning to psychedelic medicine in force, with the sector raising more than US$1 billion in a single ...

LSD has moved a significant step closer to becoming an approved prescription medicine after Definium Therapeutics reported positive topline results ...

LSD occupies a uniquely complicated position in the history of psychedelic medicine. Few compounds have had such an outsized influence ...